• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » CardioNet beats shareholder lawsuit

CardioNet beats shareholder lawsuit

August 12, 2010 By MassDevice staff

BEAT logo

CardioNet Inc. (NSDQ:BEAT) won a lawsuit filed against it by shareholders last year, accusing the mobile cardiac monitoring firm of misleading investors about Medicare reimbursement.

Judge Stewart Dalzell of the U.S. District Court for Eastern Pennsylvania granted Conshohocken, Pa.-based CardioNet’s move to dismiss the case August 10, calling on each aprty to bear its own legal costs.

The suit, filed in August 2009, accused CardioNet, then-president and CEO Randy Thurman and CFO Martin Galvan of issuing too-aggressive earnings forecasts that sent the company’s stock soaring to artificially high levels.

Shares reached $19.60 May 19, according to court documents, after the company released its guidance for 2009 through 2011. But on June 30, CardioNet lowered its 2009 guidance and rescinded its forecast for 2010 and 2011 “based on lower-than-anticipated commercial reimbursement rates,” according to the documents.

That sent shares plunging more than 41 percent to $9.57 July 1, down from $16.32 on June 30.

Then came news that Pennsylvania’s Medicare carrier, Highmark Medicare Services, was slashing its reimbursement rate for Mobile Cardiac Outpatient Telemetry by 33 percent.

That prompted CardioNet to rescind its 2009 guidance and sent share prices down another 34 percent, from $8.83 to a $5.87 close July 13.

CardioNet argued that it approached the Centers for Medicare and Medicaid and Highmark directly and was assured that neither had communicated with a Jefferies & Co. analyst who predicted the rate cut in April 2009. In addition, its public statements about the reimbursement issue included "fair warning" language cautioning investors, according to court documents.

“We are pleased with the Court’s ruling and believe that the facts in the case clearly supported the Company’s position,” current president and CEO Joe Capper said in prepared remarks.

Filed Under: Business/Financial News, Digital Health, Legal News, News Well, Software / IT Tagged With: CardioNet Inc.

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy